Filing Flows › BridgeBio Pharma (BBIO) › Q3 2026
BridgeBio Pharma (BBIO) Q3 2026 earnings results (third quarter 2026)
10-Q filed Oct 29, 2026
BridgeBio Pharma (BBIO) reported revenue of $353M for the third quarter 2026 (Q3 2026), +193% from a year earlier and +45% from the quarter before. Operating margin was -3.3%, net loss $60.5M (17.1% of revenue).
BridgeBio Pharma, Q3 2026: revenue $353M (+193% year over year), operating margin -3.3%, net loss $60.5M, operating cash flow −$44.2M. The chart follows the revenue to costs, profit and cash.
| Q3 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $353M | +45% | +193% |
| Operating profit | −$11.6M | — | — |
| Net earnings | −$60.5M | — | — |
| Operating cash flow | −$44.2M | — | — |
What changed
Revenue was $353.2M in Q3 2026, up 193% year over year and up 45% from the previous quarter. Net product revenue was the largest line at 72% of revenue. Net product revenue added $145.2M year over year (up 134%), 62% of the total change.
Operating costs exceeded revenue by $11.6M, an operating margin of -3.3%. Total costs grew 37% against revenue growth of 193%. The fastest-growing cost line was Cost of revenue (+212%). The quarter ended with a net loss of $60.5M, narrower than the previous quarter's $155.9M loss. Minority interests bore $3.8M of it: to shareholders the quarter was a loss of $56.7M. Net interest and other expense of $47.6M was the main reason.
Operating cash flow was −$44.2M. Non-cash charges added back $1.1M of depreciation and amortization and $39.9M of share-based compensation. Working capital and other items used $24.6M. Capital expenditures of $290K exceeded it, leaving free cash flow of −$44.5M.
Questions
What was BridgeBio Pharma's revenue in the third quarter 2026?
BridgeBio Pharma (BBIO) reported revenue of $353M for the third quarter 2026 (Q3 2026), +193% from a year earlier and +45% from the quarter before.
Was BridgeBio Pharma profitable in the third quarter 2026?
Operating loss was $11.6M (-3.3% of revenue) and net loss $60.5M.
Source: BridgeBio Pharma 10-Q on SEC EDGAR.